<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940626</url>
  </required_header>
  <id_info>
    <org_study_id>ASN100-201</org_study_id>
    <secondary_id>2016-002146-23</secondary_id>
    <nct_id>NCT02940626</nct_id>
  </id_info>
  <brief_title>Prevention of S. Aureus Pneumonia Study in Heavily Colonized, Mechanically Ventilated Subjects</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arsanis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arsanis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the prevention of Staphylococcus aureus pneumonia in
      mechanically ventilated subjects heavily colonized with S. aureus. Staphylococcus aureus is
      a human pathogenic bacterium that causes severe infections, including pneumonia and sepsis.
      Hospital-acquired bacterial pneumonia (HABP) caused by S. aureus, including
      ventilator-associated bacterial pneumonia (VABP) in mechanically ventilated subjects, is a
      significant public health threat despite efforts to optimize antibiotic treatment. ASN100 is
      an investigational monoclonal antibody product that targets the toxins produced by S. aureus
      to protect subjects from developing S. aureus pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, single-dose, placebo-controlled study of ASN100 for the
      prevention of S. aureus pneumonia in mechanically ventilated subjects who are heavily
      colonized with S. aureus. This will be a global study conducted at approximately 65 sites to
      assess the safety, tolerability, and efficacy of ASN100.

      Eligible subjects who meet all of the inclusion criteria and none of the exclusion criteria
      will be screened by semi-quantitative culture of an endotracheal aspirate (ETA) to identify
      those who are heavily colonized with S. aureus (3+ to 4+). Upon determination of
      eligibility, subjects will be randomized in a 1:1 ratio to 1 of 2 treatment groups, ASN100
      or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of a single intravenous (IV) dose of ASN100 as measured by clinical symptoms of pneumonia</measure>
    <time_frame>Incidence of S. aureus pneumonia through Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of intravenous (IV) doses of ASN100 as measured by adverse events and clinical laboratory parameters</measure>
    <time_frame>through Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>21 days</time_frame>
    <description>Duration of mechanical ventilation during the first 21 days post-randomization for subjects in the Modified Intent-to-Treat (MITT), Intent-to-Treat (ITT), and Per Protocol (PP) populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>21 days</time_frame>
    <description>Length of ICU stay during the first 21 days post-randomization for subjects in the MITT, ITT, PP populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day all-cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28-day all-cause mortality in the MITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ASN-1 and ASN-2 Maximum serum concentration (Cmax)</measure>
    <time_frame>through Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ASN-1 and ASN-2 Time to maximum serum concentration (Tmax)</measure>
    <time_frame>through Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ASN-1 and ASN-2 Area under the serum concentration-time curve</measure>
    <time_frame>through Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ASN-1 and ASN-2 Terminal elimination half-life (t1/2)</measure>
    <time_frame>through Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Pneumonia, Ventilator-associated</condition>
  <condition>Pneumonia, Staphylococcal</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as 2 separate intravenous (IV) infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASN100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASN100 administered as 2 separate intravenous (IV) infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASN100</intervention_name>
    <description>monoclonal antibody combination of ASN-1 and ASN-2</description>
    <arm_group_label>ASN100</arm_group_label>
    <other_name>ASN-1 and ASN-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is currently hospitalized and is mechanical ventilated endotracheally.

        Exclusion Criteria:

          -  Subject has a chest X-ray or thoracic computed tomography (CT) scan consistent with
             diagnosis of pneumonia

          -  Traumatic chest injury with paradoxical breathing or congestive cardiac failure with
             bilateral infiltrates

          -  Known heavy colonization or infection with a Gram-negative organism

          -  Neutropenia

          -  Severe non-pulmonary source of infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arsanis, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Arsanis, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Muir, CCRA</last_name>
    <phone>781-819-5704</phone>
    <email>lori.muir@arsanis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ed Campanaro, BSN, MSHS</last_name>
    <phone>781-819-5961</phone>
    <email>ed.campanaro@arsanis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-950</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>28025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>October 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>S. aureus</keyword>
  <keyword>Mechanically ventilated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pneumonia, Staphylococcal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
